A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Monday, February 13, 2017
Ampyra Works Long-Term for MS Patients With Gait Disturbance
treatment with prolonged-release fampridine (Ampyra) offered persistent
clinical and subjective benefits in walking function in gait-impaired patients
with multiple sclerosis (MS), researchers reported.
In an extension
study of the FAMPKIN trial, MS patients had an 11.5% improvement in walking
speed, a 10.7% improvement in endurance, and a 6.1-point improvement in
self-perceived ambulatory function over baseline during the first open-label
year of treatment, according to Linard Filli, PhD, of University Hospital
Zurich, and colleagues.
remained stable during a follow-up year of double-blind controlled treatment,
with improvements in those respective endpoints of 13.1%, 12%, and 7.4 points
compared with placebo, they reported online in Neurology.